METHOD FOR PREVENTING EROSIVE AND ULCERATIVE LESIONS OF STOMACH AND DUODENUM DURING CHEMOTHERAPY Russian patent published in 2023 - IPC A61K35/741 A61K31/4184 A61K31/616 A61P31/04 A61P35/00 A61P1/04 

FIELD: medicine.

SUBSTANCE: used for the prevention of erosive and ulcerative lesions of the stomach and duodenum during chemotherapy. Patients with localized or locally advanced tumors of the colon and rectosigmoid in the postoperative period for 10 days before starting chemotherapy with 5-fluorouracil take rabeprazole 20 milligrams 2 times a day, amoxicillin 1000 milligrams 2 times a day, josamycin 1000 milligrams 2 once a day, probiotic Lactobacillus reuteri DSMZ17648, 1 capsule 2 times a day during meals. Then, for maintenance purposes, they continue to take the probiotic Lactobacillus reuteri DSMZ17648, 1 capsule 2 times a day during meals for 18 days, as well as rabeprazole 20 milligrams 1 time a day and rebamipide 100 milligrams 3 times a day for 6 months throughout adjuvant chemotherapy programs including 5-fluorouracil.

EFFECT: improving long-term results of treatment of colon and rectosigmoid cancer through complete and timely administration of adjuvant cytotoxic chemotherapy containing 5-fluorouracil, as well as ensuring a high quality of life for the patient undergoing this treatment.

1 cl, 3 ex